Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.
If you are not happy with the results below please do another search
50 search results for:
With $19 million in seed funding led by the Retinal Degeneration Fund, Opus Genetics launched with a mission to develop gene therapies for rare forms of blindness driven by genetic mutations.
As a global pandemic has reshaped society, The Bloc has been at the forefront of changing not just what stories get told about healthcare, but how they are told. In doing so, the health creative agency has won more than 200 film and advertising awards during 2020 and 2021.
A potential vaccine from China’s Clover Biopharmaceuticals was 67 percent effective against Covid-19 of any degree of severity and 79 percent against the highly infectious Delta variant in a large trial, the company said on Sept. 22.
The U.S. Food and Drug Administration on Sept. 21 approved Incyte Corp.’s cream Opzelura for treating the inflammatory skin condition atopic dermatitis, commonly called eczema, in adolescents and adults with boxed warnings.
The United States plans to donate an additional 500 million Covid-19 vaccines made by Pfizer Inc. and BioNTech SE to nations around the world, lifting the total the country is sharing to more than 1 billion doses, according to a source familiar with the plans.
Novartis is expanding the Swiss pharma giant’s optogenetics portfolio with the acquisition of gene therapy company Arctos Medical.
Dr. Bethany Valente, founder and managing partner of Tempo7 LLC, discusses the challenges that biotech and pharma-based businesses face as they work to create more efficient development time frames for product, therapy, or drug development. Dr. Valente says open innovation helps in resolving some of these challenges.
AbelsonTaylor promoted Dave Schafer to director of digital production and quality assurance.
Shares of Verrica Pharmaceuticals plunged after the company received a Complete Response Letter from the U.S. Food and Drug Administration for an experimental treatment for molluscum contagiosum (molluscum).